Dr. Wagaskar on the Rationale to Evaluate the Obesity Paradox in Prostate Cancer

Video

Vinayak G. Wagaskar, MBBS, discusses the rationale to evaluate the relationship between obesity paradigm and outcomes in prostate cancer.

Vinayak G. Wagaskar, MBBS, instructor of urology, Mount Sinai, discusses the rationale to evaluate the relationship between obesity and outcomes in prostate cancer.

Several studies have emerged suggesting that morbidly obese individuals with genitourinary malignancies with a high body mass index (BMI) have improved survival compared with patients with a lower BMI, says Wagaskar. This is known as the obesity paradox because the belief is that obese patients would have naturally worse outcomes vs non-obese patients, Wagaskar says.

During the 2021 EAU Congress, findings from a retrospective study demonstrated that BMI is a significant predictor of overall survival in patients with metastatic castration-resistant prostate cancer. Moreover, obese patients had a higher survival probability vs overweight and normal weight patients.

Related Videos
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD
Sundar Jagannath, MBBS
Nikhil Gopal, MD, assistant professor, urology, College of Medicine, Memphis Department of Urology, The University of Tennessee Health Science Center
Ashwin Kishtagari, MD